TechFlow to a report by GLOBE NEWSWIRE on November 4th, Nasdaq-listed biopharmaceutical company Propanc Biopharma (PPCB) announced a strategic acquisition plan targeting Digital Asset Treasury (DAT), a company with a market capitalization below its net asset value.
The company's management believes that acquiring undervalued DAT entities will help strengthen the balance sheet, diversify assets, and create long-term shareholder value. These DAT companies typically hold significant reserves of mainstream digital assets such as Bitcoin and Ethereum on their balance sheets.
CEO James Nathanielsz stated that this is a strategic diversification initiative designed to unlock value for shareholders while continuing to advance the innovative oncology pipeline. The company's board of directors and executive team are evaluating potential acquisition targets.
Previously , Propanc Biopharma announced plans to acquire $100 million worth of Ethereum.
